Tech Company Financing Transactions
Somite Therapeutics Funding Round
On 9/3/2024, Somite Therapeutics raised $4.8 million in Seed financing from Astellas Venture Capital and private investors.
Transaction Overview
Company Name
Announced On
9/3/2024
Transaction Type
Venture Equity
Amount
$4,800,000
Round
Seed
Investors
Astellas Venture Capital (Nagisa Sakurai)
private investors (Kendra Harris)
private investors (Nachum Shamir)
private investors (Paul Harris)
Proceeds Purpose
The additional funding will be used to expedite data generation to train Somite's AI platform, AlphaStem, advance SMT-M01 toward the clinic, start a second clinical program, SMT-B01, using brown adipocytes to treat metabolic disorders, and begin research with hypoimmune cell lines.
Company Information
Company Status
Private & Independent
Industry
Artificial Intelligence
Mailing Address
240 Longwood Ave, Building C
Boston, MA 02115
USA
Boston, MA 02115
USA
Phone
Undisclosed
Website
Email Address
Overview
Somite.ai is leveraging big data and AI to introduce novel cell replacement therapies. We're developing a digital twin of the embryo, i.e. a computational model that simulates the real embryo's development and behavior to guide decision-making.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Micha Breakstone
Chief Scientific Officer
Carl Morris
Chief Technical Officer
Jonathan Rosenfeld
Co-Founder
Allon Klein
Co-Founder
Olivier Pourquie
Co-Founder
Cliff Tabin
VP - Bus. Development
Kristy Brown
Browse more venture capital transactions:
Prev: 9/3/2024: Skillvue venture capital transaction
Next: 9/3/2024: IdentifAI venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs